Cargando…

The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients

BACKGROUND: The objective of this article was to investigate the effect of as-needed nalmefene on health-related quality of life (HRQoL) in patients with alcohol dependence, and to relate changes in drinking behavior and status to HRQoL outcomes. METHODS: This post hoc analysis was conducted on a po...

Descripción completa

Detalles Bibliográficos
Autores principales: François, Clément, Rahhali, Nora, Chalem, Ylana, Sørensen, Per, Luquiens, Amandine, Aubin, Henri-Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460126/
https://www.ncbi.nlm.nih.gov/pubmed/26053024
http://dx.doi.org/10.1371/journal.pone.0129289
_version_ 1782375325605298176
author François, Clément
Rahhali, Nora
Chalem, Ylana
Sørensen, Per
Luquiens, Amandine
Aubin, Henri-Jean
author_facet François, Clément
Rahhali, Nora
Chalem, Ylana
Sørensen, Per
Luquiens, Amandine
Aubin, Henri-Jean
author_sort François, Clément
collection PubMed
description BACKGROUND: The objective of this article was to investigate the effect of as-needed nalmefene on health-related quality of life (HRQoL) in patients with alcohol dependence, and to relate changes in drinking behavior and status to HRQoL outcomes. METHODS: This post hoc analysis was conducted on a pooled subgroup of patients with at least a high drinking risk level (men: >60 g/day; women: >40 g/day) who participated in one of two randomized controlled 6-month studies, ESENSE 1 and ESENSE 2. Patients received nalmefene 18 mg or placebo on an as-needed basis, in addition to a motivational and adherence-enhancing intervention (BRENDA). At baseline and after 12 and 24 weeks questionnaires for the Medical Outcomes Study (MOS) 36-item Short-Form Health Survey (SF-36), European Quality of life-5 Dimensions (EQ-5D) and the Drinker Inventory of Consequences (DrInC-2R) were completed. RESULTS: The pooled population consisted of 667 patients (nalmefene: 335; placebo: 332), with no notable between-group differences in baseline patient demographics/characteristics. At week 24, nalmefene had a superior effect compared to placebo in improving SF-36 mental component summary scores (mean difference [95% CI], p-value: 3.09 [1.29, 4.89]; p=0.0008), SF-36 physical component summary scores (1.23 [0.15, 2.31]; p=0.026), EQ-5D utility index scores (0.03 [0.00, 0.06]; p=0.045), EQ-5D health state scores (3.46 [0.75, 6.17]; p=0.012), and DrInC-2R scores (-3.22 [-6.12, 0.33]; p=0.029). The improvements in SF-36 mental component summary scores at week 24, and the DrInC-2R total score change from baseline to week 24, were significantly correlated to reductions in heavy drinking days and total alcohol consumption at week 24. CONCLUSIONS: As-needed nalmefene significantly improved almost all patient-reported HRQoL measures included in SF-36 and EQ-5D compared with placebo. These HRQoL gains were significantly correlated to reduced drinking behavior, as determined by reductions in heavy drinking days and total alcohol consumption.
format Online
Article
Text
id pubmed-4460126
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44601262015-06-16 The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients François, Clément Rahhali, Nora Chalem, Ylana Sørensen, Per Luquiens, Amandine Aubin, Henri-Jean PLoS One Research Article BACKGROUND: The objective of this article was to investigate the effect of as-needed nalmefene on health-related quality of life (HRQoL) in patients with alcohol dependence, and to relate changes in drinking behavior and status to HRQoL outcomes. METHODS: This post hoc analysis was conducted on a pooled subgroup of patients with at least a high drinking risk level (men: >60 g/day; women: >40 g/day) who participated in one of two randomized controlled 6-month studies, ESENSE 1 and ESENSE 2. Patients received nalmefene 18 mg or placebo on an as-needed basis, in addition to a motivational and adherence-enhancing intervention (BRENDA). At baseline and after 12 and 24 weeks questionnaires for the Medical Outcomes Study (MOS) 36-item Short-Form Health Survey (SF-36), European Quality of life-5 Dimensions (EQ-5D) and the Drinker Inventory of Consequences (DrInC-2R) were completed. RESULTS: The pooled population consisted of 667 patients (nalmefene: 335; placebo: 332), with no notable between-group differences in baseline patient demographics/characteristics. At week 24, nalmefene had a superior effect compared to placebo in improving SF-36 mental component summary scores (mean difference [95% CI], p-value: 3.09 [1.29, 4.89]; p=0.0008), SF-36 physical component summary scores (1.23 [0.15, 2.31]; p=0.026), EQ-5D utility index scores (0.03 [0.00, 0.06]; p=0.045), EQ-5D health state scores (3.46 [0.75, 6.17]; p=0.012), and DrInC-2R scores (-3.22 [-6.12, 0.33]; p=0.029). The improvements in SF-36 mental component summary scores at week 24, and the DrInC-2R total score change from baseline to week 24, were significantly correlated to reductions in heavy drinking days and total alcohol consumption at week 24. CONCLUSIONS: As-needed nalmefene significantly improved almost all patient-reported HRQoL measures included in SF-36 and EQ-5D compared with placebo. These HRQoL gains were significantly correlated to reduced drinking behavior, as determined by reductions in heavy drinking days and total alcohol consumption. Public Library of Science 2015-06-08 /pmc/articles/PMC4460126/ /pubmed/26053024 http://dx.doi.org/10.1371/journal.pone.0129289 Text en © 2015 François et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
François, Clément
Rahhali, Nora
Chalem, Ylana
Sørensen, Per
Luquiens, Amandine
Aubin, Henri-Jean
The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients
title The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients
title_full The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients
title_fullStr The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients
title_full_unstemmed The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients
title_short The Effects of as-Needed Nalmefene on Patient-Reported Outcomes and Quality of Life in Relation to a Reduction in Alcohol Consumption in Alcohol-Dependent Patients
title_sort effects of as-needed nalmefene on patient-reported outcomes and quality of life in relation to a reduction in alcohol consumption in alcohol-dependent patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4460126/
https://www.ncbi.nlm.nih.gov/pubmed/26053024
http://dx.doi.org/10.1371/journal.pone.0129289
work_keys_str_mv AT francoisclement theeffectsofasneedednalmefeneonpatientreportedoutcomesandqualityoflifeinrelationtoareductioninalcoholconsumptioninalcoholdependentpatients
AT rahhalinora theeffectsofasneedednalmefeneonpatientreportedoutcomesandqualityoflifeinrelationtoareductioninalcoholconsumptioninalcoholdependentpatients
AT chalemylana theeffectsofasneedednalmefeneonpatientreportedoutcomesandqualityoflifeinrelationtoareductioninalcoholconsumptioninalcoholdependentpatients
AT sørensenper theeffectsofasneedednalmefeneonpatientreportedoutcomesandqualityoflifeinrelationtoareductioninalcoholconsumptioninalcoholdependentpatients
AT luquiensamandine theeffectsofasneedednalmefeneonpatientreportedoutcomesandqualityoflifeinrelationtoareductioninalcoholconsumptioninalcoholdependentpatients
AT aubinhenrijean theeffectsofasneedednalmefeneonpatientreportedoutcomesandqualityoflifeinrelationtoareductioninalcoholconsumptioninalcoholdependentpatients
AT francoisclement effectsofasneedednalmefeneonpatientreportedoutcomesandqualityoflifeinrelationtoareductioninalcoholconsumptioninalcoholdependentpatients
AT rahhalinora effectsofasneedednalmefeneonpatientreportedoutcomesandqualityoflifeinrelationtoareductioninalcoholconsumptioninalcoholdependentpatients
AT chalemylana effectsofasneedednalmefeneonpatientreportedoutcomesandqualityoflifeinrelationtoareductioninalcoholconsumptioninalcoholdependentpatients
AT sørensenper effectsofasneedednalmefeneonpatientreportedoutcomesandqualityoflifeinrelationtoareductioninalcoholconsumptioninalcoholdependentpatients
AT luquiensamandine effectsofasneedednalmefeneonpatientreportedoutcomesandqualityoflifeinrelationtoareductioninalcoholconsumptioninalcoholdependentpatients
AT aubinhenrijean effectsofasneedednalmefeneonpatientreportedoutcomesandqualityoflifeinrelationtoareductioninalcoholconsumptioninalcoholdependentpatients